Especifique uma ação ou criptomoeda na barra de pesquisa para obter um resumo
Abliva AB
ABLIAbliva AB (publ) discovers and develops medicines for the treatment of mitochondrial disease in Sweden. The company is developing KL1333 that is in Phase 2 clinical trial to treat chronic fatigue and myopathy in genetically confirmed adult patients with primary mitochondrial disease; and NV354, which has completed preclinical development for the treatment of mitochondrial disease with neurologic complications. It has a licensing and collaboration agreement with Owl Therapeutics for NeuroSTAT for the treatment of traumatic brain injury; and Yungjin Pharm on the clinical development of the KL1333, as well as Isomerase, Children's Hospital of Philadelphia, Newcastle University and University College London, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden. Address: Medicon Village, Lund, Sweden, 223 81
Analytics
Preço Alvo de Wall Street
10.87 SEKRácio P/E
–Rendimento de dividendos
–Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Ano atual
Ano passado
Trimestre Atual
Ultimo quarto
Figuras chave ABLI
Análise de Dividendos ABLI
Crescimento de dividendos em 5 anos
–Crescimento contínuo
–Taxa de pagamento em média de 5 anos
–Histórico de Dividendos ABLI
Avaliação de ações ABLI
Relatório ABLI
Acompanhe as principais métricas de cada ação em um só lugar, sem complicações
Inscreva-se no premiumResultados | 2019 | Dinâmica |